MuSK MG clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
open to eligible people ages 18-75
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Orange, California and other locations
Our lead scientists for MuSK MG research studies include Ali A Habib, MD.
Last updated: